Ticker

LOS ANGELES, March 16, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). IF YOU SUFFERED A LOSS ON YOUR INOVIO INVESTMENTS, CLICK  HERE BEFORE APRIL 7, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT…

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that…

LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Inovio Pharmaceuticals, Inc., (“Inovio” or the "Company") (NASDAQ: INO) investors of a class action on behalf of investors that bought securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”). Inovio investors have until April 7, 2026 to file a lead plaintiff motion.

LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who…

NEW YORK, March 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 7, 2026 lead plaintiff deadline.